BILB-1941

CAS No. 494856-61-0

BILB-1941( —— )

Catalog No. M34180 CAS No. 494856-61-0

BILB-1941 (BILB-1941ZW) is an inhibitor of HCV NS5B polymerase and can be used in studies about HCV infection.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 500 Get Quote
5MG 758 Get Quote
10MG 1036 Get Quote
25MG 1518 Get Quote
50MG 2052 Get Quote
100MG 2637 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    BILB-1941
  • Note
    Research use only, not for human use.
  • Brief Description
    BILB-1941 (BILB-1941ZW) is an inhibitor of HCV NS5B polymerase and can be used in studies about HCV infection.
  • Description
    BILB 1941 is a potent and specific nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase in vitro.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    HCV Protease
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    494856-61-0
  • Formula Weight
    562.66
  • Molecular Formula
    C34H34N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CN1C(=C(C=2C1=CC(C(NC3(C(NC4=CC=C(/C=C/C(O)=O)C=C4)=O)CCC3)=O)=CC2)C5CCCC5)C6=CC=CC=N6
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Erhardt A, et al. Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment. Antivir Ther. 2009;14(1):23-32.?
molnova catalog
related products
  • Methyl hexadecanoate

    Used as an intermediate of emulsifier, wetting agent, stabilizer and plasticizer.

  • MRT-2359

    MRT-2359 is a potent and orally available GSPT1 reducer with antitumour activity.MRT-2359 inhibits the growth of drug-resistant non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells.MRT-2359 exhibits preferential activity in MYC-driven cell lines.

  • IFN-γ Antagonist

    IFN-γ Antagonist